Reported Earlier, Medtronic's MiniMed 780G Shows Data on Hyperglycemia and Nighttime Relief
Portfolio Pulse from Benzinga Newsdesk
Medtronic plc (NYSE:MDT) presented new data at the American Diabetes Association's 84th Scientific Sessions showcasing the benefits of its MiniMed™ 780G system in addressing hyperglycemia and reducing nighttime burden for diabetes patients. The data highlights significant improvements in managing high blood sugar levels and reducing sleep disruptions compared to the previous MiniMed™ 770G system.
June 24, 2024 | 6:57 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medtronic's new data on the MiniMed™ 780G system shows significant improvements in managing hyperglycemia and reducing nighttime burden for diabetes patients, which could boost the company's market position and drive revenue growth.
The new data presented by Medtronic demonstrates significant improvements in diabetes management with the MiniMed™ 780G system, which is likely to enhance the company's market position and drive revenue growth. The positive clinical outcomes and reduced burden for patients can lead to increased adoption of the system.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100